**INTRODUCTION:** The use of antithrombotics and other blood thinners in plastic surgery flap reconstruction remains inconsistent among practitioners. Previous animal studies have demonstrated favorable effects of antithrombotics by inhibiting anastomotic venous thrombosis and improving microcirculatory perfusion. However, these results have yet to translate into definitive clinical benefits in human studies, with the majority resulting in increased hematoma development. We aim to revisit this topic with the use of a large database and examine in-hospital complications, most notably flap failure and hematoma, in patients on various long-term blood thinners.

**METHODS:** Patients who underwent non-breast pedicled or free-flap reconstruction from 2013 to 2014 were identified from the Healthcare Utilization Cost Project National Inpatient Sample (NIS) Database. De-identified data on patient demographics, perioperative risk factors and incidence of complications were obtained. Outcomes of interest included flap failure and hematoma formation. Logistic regression was used to assess the adjusted effect of long-term antithrombotic/anticoagulant or aspirin use on flap failure and hematoma formation.

**RESULTS:** The study population included 79,915 patients. Of these patients, 3,775 (4.7%) took an anticoagulant/ antithrombotic and 4,575 (5.7%) took aspirin preoperatively. Patients on either one of the blood thinners were more likely to be smokers (p\<0.001), have more comorbidities (p\<0.001), have peripheral vascular disorders (p\<0.001), be hypertensive (p\<0.001), male (p\<0.001) and be obese (p\<0.001). Overall rates of flap failure and hematoma formation were 2.5 percent and 2.6 percent, respectively. Unadjusted flap failure rates were 2.4 percent and 2.7 percent for anticoagulant/antithrombotics and aspirin, respectively. Unadjusted hematoma rates were 7.0 percent and 3.7 percent for anticoagulants/antithrombotics and aspirin respectively. On multivariate regression there was a significant increase in odds of hematoma formation associated with anticoagulation/antithrombotic use (OR=2.413, p\<0.001); however, no difference in hematoma formation for those on aspirin therapy (OR=1.070, p=0.427). There was a non-significant reduction in flap failure rates for patients on anticoagulants/antithrombotics (OR=0.802, p=0.062) and no significant difference in aspirin use on flap failure rates (OR=1.146, p=0.159).

**CONCLUSION:** Our results show there was no significant difference in anticoagulants/antithrombotic or aspirin use in terms of flap failure with an increase in hematoma rates for the former. Additional prospective studies should clarify whether the variety of blood thinners can improve outcomes while still minimizing complication rates in flap reconstruction.
